Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Canakinumab (ACZ885)
DRUG
2 trials
Sponsors
Novartis
, Novartis Pharmaceuticals
Conditions
Cryopyrin-Associated Periodic Syndromes
Familial Cold Autoinflammatory Syndrome
Muckle Wells Syndrome
Neonatal Onset Multisystem Inflammatory Disease
Peripheral Artery Disease
Phase 2
Safety, Tolerability and Efficacy of ACZ885 on Leg Artery Structure in Patients With Peripheral Artery Disease
Terminated
NCT01731990
Novartis Pharmaceuticals
Peripheral Artery Disease
Start: 2012-10-30
End: 2016-08-04
Updated: 2025-04-29
Phase 3
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Completed
NCT00685373
Novartis
Cryopyrin-Associated Periodic Syndromes, Familial Cold Autoinflammatory Syndrome, Muckle Wells Syndrome +1
Start: 2008-05-31
End: 2010-04-30
Updated: 2016-11-04
Related Papers
A randomized, placebo-controlled trial of canakinumab in patients with peripheral artery disease
Vascular Medicine
2019-07-05
50 citations
Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes.
2011-08-21
152 citations